Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab efficacy in rheumatoid arthritis after inadequate response or contraindication to anti-TNF therapy
ISRCTN21216199Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab + methotrexate with Placebo then tocilizumab + methotrexate (2 arms). Primary endpoint: Synovial tissue changes. Started Apr 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN21216199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21216199.